BET Bromodomain Inhibitor ZEN-3694

Phase 2Small molecule

BET Bromodomain Inhibitor ZEN-3694 is one of 80 small molecule programs targeting Recurrent Endometrial Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Endometrial CarcinomaRecruiting

Advanced Malignant Solid NeoplasmRecruiting

Metastatic Colorectal CarcinomaRecruiting

Advanced NUT CarcinomaRecruiting

Castration-Resistant Prostate CarcinomaActive, not recruiting

Anatomic Stage III Breast Cancer AJCC V8Recruiting

Recurrent Endometrial CarcinomaPhase 1

Recruiting

Advanced Malignant Solid NeoplasmPhase 2

Recruiting

Metastatic Colorectal CarcinomaPhase 1

Recruiting

Advanced NUT CarcinomaPreclinical

Recruiting

Castration-Resistant Prostate CarcinomaPhase 2

Active, not recruiting

Anatomic Stage III Breast Cancer AJCC V8Phase 1

Recruiting

Competition

Competitive Landscape

43 competitors in Advanced Malignant Solid Neoplasm

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Phase 3

2 2

Lynparza

AstraZeneca

Phase 2

4 3

Ibrance

Pfizer

Phase 2

4 4

Mektovi

Pfizer

Phase 2

2 5

Taxol

Teva

Phase 2

2 6

Koselugo

AstraZeneca

Phase 2

2 7

Keytruda

Merck & Co.

Phase 2

1 8

Talzenna

Pfizer

Phase 2

1 9

Balversa

Johnson & Johnson

Phase 2

1 10

Retevmo

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Metastatic Colorectal Adenocarcinoma

NCT06102902

Phase 1Recruiting

Advanced Malignant Solid Neoplasm

NCT05111561

Phase 1Recruiting

Anatomic Stage III Breast Cancer AJCC V8

NCT05422794

Q2 2027

Phase 1Recruiting

Anatomic Stage III Breast Cancer AJCC V8

NCT05372640

PreclinicalRecruiting

Advanced NUT Carcinoma

NCT05019716

Phase 1Recruiting

Recurrent Endometrial Carcinoma

NCT05950464

Clinical

Trials by Indication[1]

Advanced Malignant Solid Neoplasm3 trials

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05327010·88 enrolled

A Phase 1 Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05111561·42 enrolled

Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05053971·49 enrolled

Anatomic Stage III Breast Cancer AJCC v82 trials

A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05422794·57 enrolled

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05372640·45 enrolled

Metastatic Colorectal Adenocarcinoma1 trial

A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06102902·30 enrolled

Recurrent Endometrial Carcinoma1 trial

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05950464·65 enrolled

Metastatic Colorectal Carcinoma1 trial

Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05803382·30 enrolled

3 more indications

Metastatic Malignant Solid Neoplasm1 trial

Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors

Suspended·NNational Cancer Institute (NCI)·Phase 1·NCT04840589·66 enrolled

Advanced NUT Carcinoma1 trial

A Phase 1 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Platinum-based Chemotherapy in Patients With NUT Carcinoma

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05019716·36 enrolled

Castration-Resistant Prostate Carcinoma1 trial

A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·RRahul Aggarwal·Phase 2·NCT04471974·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for BET Bromodomain Inhibitor ZEN-3694. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BET Bromodomain Inhibitor ZEN-3694 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BET Bromodomain Inhibitor ZEN-3694. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

BET Bromodomain Inhibitor ZEN-3694

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Advanced Malignant Solid Neoplasm3 trials

Anatomic Stage III Breast Cancer AJCC v82 trials

Metastatic Colorectal Adenocarcinoma1 trial

Recurrent Endometrial Carcinoma1 trial

Metastatic Colorectal Carcinoma1 trial

Metastatic Malignant Solid Neoplasm1 trial

Advanced NUT Carcinoma1 trial

Castration-Resistant Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News